HealthEquity (HQY) is trading higher today as investors react to a bullish analyst reset: BMO upgraded the shares to Outperform and increased its price target to $105 from $85. That kind of rating change can quickly pull in incremental buyers—particularly in mid-to-large cap names where institutional positioning tends to follow target and rating revisions. (sahmcapital.com)

The upgrade lands after HealthEquity’s fiscal Q4 and full-year fiscal 2026 update (released March 17, 2026), when the company posted a notable earnings beat and paired it with an upbeat forward view. Investors have been focused on the company’s ability to expand margins and sustain growth, and the market has also been watching how HealthEquity’s HSA cash portfolio reprices over time—an important earnings lever in the current rate environment. (stocktitan.net)

The next catalysts are additional analyst revisions, management commentary around deposit yields and the HSA cash repricing timeline, and any incremental disclosures that reshape confidence in execution. Traders will also watch whether the rally holds on volume and whether follow-through buying appears into the next earnings window (often estimated in early June based on past timing). (ir.healthequity.com)